Vertex Pharmaceuticals — Valuation, Funding & Investors

We're still building this profile — here is what Pulse has covered.

Latest Pulse

Aug 4, 2026Latigo Sets Terms for a $272M Nasdaq IPOLatigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.→

Coverage Timeline

newest first

Aug 4, 2026IPOLatigo Sets Terms for a $272M Nasdaq IPO$272M IPO→

All Coverage

IPO· Aug 4, 2026

Latigo Sets Terms for a $272M Nasdaq IPO

IPO$272M IPO

Latigo Sets Terms for a $272M Nasdaq IPO

Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.

Aug 4, 2026

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics